<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639180</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-III-325</org_study_id>
    <nct_id>NCT04639180</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation</brief_title>
  <official_title>A Randomized, Open-Label, Multi-Center, Phase â…¢ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib)&#xD;
      Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma&#xD;
      (HCC) at High Risk of Recurrence After Curative Resection or Ablation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Camrelizumab Combined with Rivoceranib (Apatinib) Versus Active Surveillance</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)</measure>
    <time_frame>Randomization up to approximately 43 months</time_frame>
    <description>RFS is defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by BIRC, or death from any cause (whichever occurs first).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RFS Rate at 24 and 36 Months, as Assessed by the Investigator</measure>
    <time_frame>Randomization up to 24 months and up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence (TTR) as determined by the investigator and by BIRC</measure>
    <time_frame>Randomization up to approximately 43 months</time_frame>
    <description>TTR defined as the time from randomization to first documented occurrence of local, regional, or metastatic HCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization up to approximately 43 months</time_frame>
    <description>OS is defined as the time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0</measure>
    <time_frame>Baseline up to approximately 43 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">674</enrollment>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Camrelizumab; Drug: Rivoceranib (Apatinib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (Active surveillance)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder</description>
    <arm_group_label>Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivoceranib (Apatinib)</intervention_name>
    <description>Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet</description>
    <arm_group_label>Treatment group (Camrelizumab Plus Rivoceranib (Apatinib))</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a histopathological diagnosis of HCC&#xD;
&#xD;
          -  Subjects who have undergone a curative resection or ablation (radiofrequency ablation&#xD;
             [RFA] or microwave ablation [MVA] only)&#xD;
&#xD;
          -  No previous systematic treatment and locoregional therapy for HCC prior to&#xD;
             randomization&#xD;
&#xD;
          -  Absence of major macrovascular invasion&#xD;
&#xD;
          -  No extrahepatic spread&#xD;
&#xD;
          -  Full recovery from Curative resection or ablation within 4 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  High risk for HCC recurrence after resection or ablation&#xD;
&#xD;
          -  For patients who received post-operative transarterial chemoembolization: full&#xD;
             recovery from the procedure within 4 weeks prior to randomization&#xD;
&#xD;
          -  Child-Pugh Class: Grade A&#xD;
&#xD;
          -  ECOG-PS score: 0 or 1&#xD;
&#xD;
          -  Subjects with HCV- RNA (+) must receive antiviral therapy&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and&#xD;
             fibrolamellar HCC; other active malignant tumor except HCC within 5 years or&#xD;
             simultaneously&#xD;
&#xD;
          -  Evidence of residual lesion, recurrence, and metastasis at randomization;&#xD;
&#xD;
          -  Moderate-to-severe ascites with clinical symptoms&#xD;
&#xD;
          -  History of hepatic encephalopathy&#xD;
&#xD;
          -  History of gastrointestinal hemorrhage within 6 months prior to the start of study&#xD;
             treatment or clear tendency of gastrointestinal haemorrhage&#xD;
&#xD;
          -  Active or history of autoimmune disease&#xD;
&#xD;
          -  Interstitial lung disease that is symptomatic or may interfere with the detection and&#xD;
             management of suspected drug-related pulmonary toxicity&#xD;
&#xD;
          -  Cardiac clinical symptom or cardiovascular disease that is not well controlled&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to the start of study treatment&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Known history of serious allergy to any monoclonal antibody or targeted&#xD;
             anti-angiogenic drug&#xD;
&#xD;
          -  Subjects with inadequately controlled hypertension or history of hypertensive crisis&#xD;
             or hypertensive encephalopathy&#xD;
&#xD;
          -  Thrombosis or thromboembolic event within 6 months prior to the start of study&#xD;
             treatment&#xD;
&#xD;
          -  Known genetic or acquired hemorrhage or thrombotic tendency&#xD;
&#xD;
          -  Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6&#xD;
             months prior to the start of study treatment&#xD;
&#xD;
          -  Serious non-healing or dehiscing wound&#xD;
&#xD;
          -  Major Curative procedure within four weeks&#xD;
&#xD;
          -  Factors to affect oral administration&#xD;
&#xD;
          -  Previous or current presence of metastasis to central nervous system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linna Wang, MD</last_name>
    <phone>021-60453196</phone>
    <email>linna.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Wu, MD</last_name>
    <phone>010-67166319</phone>
    <email>jing.wu@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Du Chengyou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanjin</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Bangde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pan Yaozhen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Qiang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Jia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Tianqiang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

